The MONALEESA-3 study in HR+/HER2- advanced breast cancer

Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer Author: obr Added: 07/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts